Lab-Based IVD Market Forecast to Reach USD 67.03 Billion by 2032, Driven by Automation and Rising Diagnostic Demand

The global Lab-Based IVD Market was valued at USD 42.54 billion in 2024 and is projected to reach USD 67.03 billion by 2032, expanding at a CAGR of 5.87% during the forecast period from 2025 to 2032. This growth reflects increasing reliance on laboratory-based diagnostics for accurate disease detection, monitoring, and personalized treatment, supported by technological advancements and expanding healthcare infrastructure worldwide.

Lab-based in vitro diagnostics continue to form the backbone of modern clinical decision-making, particularly in high-volume settings such as clinical laboratories and hospital diagnostic centers. Rising global disease burden, growing geriatric populations, and heightened emphasis on early diagnosis are accelerating the adoption of advanced immunodiagnostics, hematology, and molecular testing platforms across both developed and emerging markets.

Get free Sample Report@ https://www.snsinsider.com/sample-request/7677

Market Segmentation Highlights

By product type, reagents and consumables dominated the market in 2024, accounting for nearly 63% of total revenue. Their leadership is attributed to repetitive usage in routine and specialized diagnostic tests, particularly within high-throughput laboratory environments. Meanwhile, the instruments segment is expected to register the fastest growth rate, fueled by rising automation, integration of AI-enabled analyzers, and increasing installations of advanced diagnostic systems across laboratories.

From a technology perspective, immunodiagnostics held over 38% market share in 2024 due to high sensitivity, rapid turnaround times, and widespread application in infectious and chronic disease testing. Hematology-based diagnostics are also gaining traction, supported by advancements in multi-parameter analyzers and the increasing prevalence of blood-related disorders.

Blood samples represented the largest and fastest-growing sample type, contributing around 47% of the market share. Their dominance is driven by broad applicability across immunoassays, molecular diagnostics, and hematology testing, combined with ease of collection and compatibility with automated platforms.

In terms of applications, infectious disease diagnostics accounted for approximately 42% of global revenue, reflecting sustained testing volumes, enhanced disease surveillance, and continued demand for accurate pathogen detection. Other applications—including endocrinology, nephrology, and rare disease diagnostics—are expected to grow at the highest pace, aligned with rising clinical awareness and the shift toward precision and personalized medicine.

Clinical laboratories emerged as the leading end-user segment with over 54% market share in 2024. Their ability to handle complex, high-volume testing, coupled with scalable infrastructure and automation, positions them as key contributors to ongoing market expansion.

Regional Outlook

North America led the global lab-based IVD market with a 38.2% share in 2024, supported by advanced healthcare systems, strong reimbursement frameworks, and early adoption of innovative diagnostic technologies. The U.S. market alone is forecast to grow from USD 12.28 billion in 2024 to USD 17.40 billion by 2032, driven by robust R&D investments, regulatory support, and the presence of leading industry players.

Europe ranks as the second-largest market, benefiting from aging populations, national screening programs, and strong public healthcare spending. Countries such as Germany and the U.K. continue to invest heavily in immunodiagnostics, hematology, and rapid testing solutions, reinforcing regional demand.

Asia Pacific is expected to witness the fastest growth through 2032, propelled by expanding patient populations, government-backed healthcare initiatives, and rapid laboratory modernization. China, India, Japan, South Korea, and Singapore are at the forefront of adopting automated diagnostics, molecular testing, and digital pathology solutions, creating significant opportunities for market participants.

Buy Full Report Now: https://www.snsinsider.com/checkout/7677

Competitive Landscape and Recent Developments

The lab-based IVD market is moderately consolidated, with major players including F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Sysmex Corporation, Siemens Healthineers AG, BD, QIAGEN, Bio-Rad Laboratories Inc., Seegene Inc., DiaSorin S.p.A., and Quest Diagnostics Incorporated. These companies are actively investing in automation, molecular diagnostics, and precision medicine to strengthen their market positions.

Recent industry developments highlight this trend. In April 2025, Seegene introduced CURECA, a next-generation platform designed to automate PCR workflows and sample handling, underscoring the industry’s shift toward laboratory efficiency. Earlier, in February 2024, Quest Diagnostics launched MelaNodal Predict, a gene-expression assay aimed at personalizing melanoma treatment decisions, reflecting growing emphasis on precision diagnostics.

Other Trending Reports

Home Health Hub Market

Population Health Management Market

Bioprocess Validation Market

Skin Cancer Treatment Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Rohan Jadhav - Principal Consultant

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Email: info@snsinsider.com